Evidence map›Paper›PMID 17267386›Full record

ReviewFASEB journal : official publication of the Federation of American Societies for Experimental Biology2007

Resolution of inflammation: state of the art, definitions and terms.

Charles N Serhan, Sue D Brain, Christopher D Buckley, Derek W Gilroy, Christopher Haslett, Luke A J O'Neill, Mauro Perretti, Adriano G Rossi, John L Wallace

Registry-linked trialOpen access · greenAbstract readReview
In one paragraph

Review in FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03208920 (Omega EVAR), which is not on this map. Cited by 529 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
529citing papers in PubMed, 1 pooled it
19.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03208920 nacompletednot on this mapstarted 2016, after this paper: background citation

Omega EVAR: Use of Fish Oil to Reduce Inflammation During Endovascular Abdominal Aortic Repair.

TypeinterventionalSponsorUniversity of California, San FranciscoRan2016 to 2018Enrolled2ConditionsPAD, Abdominal Aortic AneurysmArmsPro-Omega, ProOmega Placebo
3 · Its place in the literature

Who cites it

529 citing papers in PubMed, 1 synthesis or guideline pooled it, 1,030 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. A synergistic multimodality treatment approach to address the key drivers of wound chronicity.Journal of vascular surgery. Venous and lymphatic disorders · 2026
    Review
  16. Review
  17. Article
  18. Article
  19. Review
  20. Lipoxin A4 AttenuatesJournal of inflammation research · 2026
    Article

469 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 9 institutions in 4 countries.

Charles N SerhanCenter for Experimental Therapeutics and Reperfusion Injury, Brigham and Women's Hospital and Harvard Medical School, 75 Francis St., Thorn 724, Boston, MA 02115, USA. cnserhan@zeus.bwh.harvard.edu
Sue D Brain
Christopher D Buckley
Derek W Gilroy
Christopher Haslett
Luke A J O'Neill
Mauro Perretti
Adriano G Rossi
John L Wallace
Centre for Inflammation Research · GBHarvard University · USKing's College London · GBThe Queen's Medical Research Institute · GBTrinity College Dublin · IEUniversity College London · GBUniversity of Birmingham · GBUniversity of Calgary · CAWilliam Harvey Research Institute · GB

Funding

Arthritis Research UK 16390Medical Research Council G0601481Medical Research Council G116/131
6 · The paper itself

Abstract

A recent focus meeting on Controlling Acute Inflammation was held in London, April 27-28, 2006, organized by D.W. Gilroy and S.D. Brain for the British Pharmacology Society. We concluded at the meeting that a consensus report was needed that addresses the rapid progress in this emerging field and details how the specific study of resolution of acute inflammation provides leads for novel anti-inflammatory therapeutics, as well as defines the terms and key components of interest in the resolution process within tissues as appreciated today. The inflammatory response protects the body against infection and injury but can itself become dysregulated with deleterious consequences to the host. It is now evident that endogenous biochemical pathways activated during defense reactions can counter-regulate inflammation and promote resolution. Hence, resolution is an active rather than a passive process, as once believed, which now promises novel approaches for the treatment of inflammation-associated diseases based on endogenous agonists of resolution.

Indexed as

AnimalsAnti-Inflammatory AgentsCytokinesHumansInflammationLeukocytesModels, BiologicalAnti-Inflammatory AgentsCytokines

Identifiers

PMID17267386
PMCPMC3119634
OpenAlexW2120699390

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.